18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
Recruiting · Phase 1 · NCT06048094
Conditions: Brain Metastases, Brain Metastases, Adult, Brain Cancer
At a glance
- Research payments reported, 2025
- $51,665
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 46
About the trial
- Sponsor
- Baptist Health South Florida (with Blue Earth Diagnostics)
- Tested
- 18F fluciclovine (drug)
- Dates
- Started 2024-04-11; completion 2033-05
- Results posted
- Not yet
This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as a biomarker to measure response or progression of brain metastasis after SRS.
From ClinicalTrials.gov, last updated 2026-05-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blue Earth Diagnostics reported $51,665 in research payments for this study in 2025 (10 payments).
Products named: Axumin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Miami Cancer Institute at Baptist Health $51,665
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.